2019 Outlook of Global Chemicals and Materials in Infrastructure and Mobility

| April 30, 2019

article image
2019 Outlook of Global Chemicals and Materials in Infrastructure and MobilitySpeakers : Soundarya ShankarKey Takeaways:This deliverable aims to paint a picture of the global chemicals and materials market for infrastructure and mobility applications in terms of key trends, top technologie.

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

OTHER ARTICLES

Petrochemicals in PA: What You Need to Know

Article | February 19, 2020

A bill recently passed by the Pennsylvania General Assembly would subsidize the use of fracked gas to produce petrochemicals. At some point—i.e., at a time chosen by the state Senate—H B 1100 will be sent to Governor Wolf, who has promised a veto despite override threats. Meanwhile, Pennsylvanians are trying to understand the bill and its potential impacts. That hasn't been easy, because as with the petrochemical subsidy bills Pennsylvania enacted in 2012, the General Assembly has not held a single hearing on the legislation. The purpose of this blog is to help fill that gap.

Read More

COVID-19’S IMPACT ON CHEMICAL SUPPLY CHAINS

Article | April 8, 2020

The global COVID-19 pandemic has resulted in significant impact on chemical supply chains. Here we take a look at some of the chemicals that have been affected: Sanitization products such as Isopropyl Alcohol have experienced skyrocketing demand. Unfortunately, manufacturers are simultaneously dealing with problems that are preventing them from supplying at full capacity. While two US producers are experiencing production issues, another is having trouble with raw material Acetone supply. A fourth US producer is scheduled to restart production of IPA, but this material will take a few weeks to come online. Meeting this unprecedented demand is proving to be a challenge, and prices have increased sharply.

Read More

Improving Pump Seal Reliability for Bay Area Petrochem Plants

Article | March 10, 2020

Keeping thousands of pumps in San Francisco Bay Area refineries running 24/7/365 requires a well-planned and well-executed maintenance strategy. Unplanned failures may have ramifications for safety, budget, and compliance—especially with regard to Bay Area Air Quality Management District (BAAQMD) regulations. One of the most mission-critical elements for smooth operations is pump seal reliability. Many plants run pumps outside the safe operating envelope and replace them only when economically feasible. Over time, however, you increasingly risk catastrophic downtime. Fortunately, you have the means to largely mitigate pump seal reliability problems with awareness and proactive management of conditions to improve safety and compliance.

Read More

How Is the SCIP Database Different From the REACH Regulation

Article | February 14, 2020

Companies operating in the European Union (EU) must submit data when introducing articles containing Substances of Very High Concern (SVHCs) above the 0.1 percent weight by weight (w/w) threshold. The reporting trigger for an in-scope article is currently derived from the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation’s Candidate List of SVHCs, but the data requirements for the SCIP database, triggered by the EU Waste Framework Directive (WFD), vary widely from those required by the REACH Regulation.

Read More

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

Events